You have 1 action to finish to complete your account. Craft your experience by picking your interest on the Personalisation Page
No matches
Pulmonology

Patient Case Discussion

Dr. Klaus Rabe discusses a hypothetical patient case.

Klaus Rabe
MD, PhD, FERS
Klaus Rabe

Learning objectives

  • Understand the role of key and central type 2 cytokines, IL-4 and IL-13, as the underlying drivers of airway remodeling and lung function decline in patients with severe asthma
  • Discuss the cyclic relationship between persistent type 2 inflammation, impaired lung function, and severe exacerbations, and their impact on the burden of severe asthma
  • Evaluate the latest biologic data in severe asthma patients

Description

Join Drs. Guy Brusselle and Klaus Rabe as they discuss the burden associated with the cycle of lung function decline and asthma exacerbations, and the role biologics can have in breaking this cycle.

Tags
type 2 inflammationlung functionbiologicscorticosteroidsremissionpatient caseguidelines
MAT-GLB-2202507 v1.0 06/2022

About this expert

Pulmonology

Klaus Rabe

MD, PhD, FERS

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

See author’s profile
Klaus Rabe

Related resources

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions
Dermatology
Infographic

The Emerging Paradigm of Atopic Dermatitis as a Lifelong Predisposition to Episodic Skin Lesions

Expert Case Series: Determining Treatment in a Pediatric Patient With Severe AD
Dermatology
interactivity

Expert Case Series: Determining Treatment in a Pediatric Patient With Severe AD

A Triad of Interacting Mechanisms Interact to Drive the Pathophysiology of AD, Asthma, CRSwNP, and EoE
Type 2 Inflammation
Infographic

A Triad of Interacting Mechanisms Interact to Drive the Pathophysiology of AD, Asthma, CRSwNP, and EoE

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics
Dermatology
interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

Prurigo Nodularis (PN) Case Studies
Dermatology
interactivity

Prurigo Nodularis (PN) Case Studies

The Role of Type 2 Inflammation in Multiple Disease Trajectories
Type 2 Inflammation
interactivity

The Role of Type 2 Inflammation in Multiple Disease Trajectories

Type 2 Inflammation and Neuronal Sensitization in AD and PN
Dermatology
interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom
Dermatology
expert video

The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom

The Next Frontier in Treatment of Atopic Dermatitis in Children
Dermatology
expert video

The Next Frontier in Treatment of Atopic Dermatitis in Children

The Role of Type 2 Inflammation in Atopic Dermatitis
Dermatology
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Type 2 Inflammation is the Predominant Pathway in AD from Infancy to Adulthood
Dermatology
expert video

Type 2 Inflammation is the Predominant Pathway in AD from Infancy to Adulthood

Why Does the Diagnosis of PN Present a Debilitating Burden of Disease for Patients?
Dermatology
expert video

Why Does the Diagnosis of PN Present a Debilitating Burden of Disease for Patients?

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis
Type 2 Inflammation
expert video

The Role of Type 2 Inflammation in the Pathophysiology of Atopic Dermatitis

The Role of IL-4 in Type 2 Inflammation
Type 2 Inflammation
expert video

The Role of IL-4 in Type 2 Inflammation

Type 2 Inflammation Drives Skin Barrier Dysfunction and Influences Change in the Skin Microbiome
Dermatology
expert video

Type 2 Inflammation Drives Skin Barrier Dysfunction and Influences Change in the Skin Microbiome

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients
Dermatology
Infographic

Recognizing the Complex, Multi-Dimensional Impact of AD on Adult Patients

Tools For a Holistic Assessment of Atopic Dermatitis Across Age Groups
Dermatology
slide presentation

Tools For a Holistic Assessment of Atopic Dermatitis Across Age Groups

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis
Dermatology
interactivity

Type 2 Inflammation, Neurosensitization, and Chronic Itch in Atopic Dermatitis

The Burden and Unmet Needs of Patients With PN
Dermatology
expert video

The Burden and Unmet Needs of Patients With PN

Skin Barrier Dysfunction and the Increased Risk For Allergen Sensitization in Children With Atopic Dermatitis
Dermatology
Infographic

Skin Barrier Dysfunction and the Increased Risk For Allergen Sensitization in Children With Atopic Dermatitis

Effect of Type 2 Inflammation on Skin Barrier Function in AD​
Dermatology
interactivity

Effect of Type 2 Inflammation on Skin Barrier Function in AD​

Eosinophilic Esophagitis (EoE) Interactive Patient Case
Gastroenterology
interactivity

Eosinophilic Esophagitis (EoE) Interactive Patient Case

EAACI 2022 | How Do Chronic Type 2 Inflammation and Airway Remodeling Translate to Lung Function Decline in Asthma?
Pulmonology
expert video

EAACI 2022 | How Do Chronic Type 2 Inflammation and Airway Remodeling Translate to Lung Function Decline in Asthma?

EAACI 2022 | Optimizing Biologic Use in Patients With Severe Asthma
Pulmonology
expert video

EAACI 2022 | Optimizing Biologic Use in Patients With Severe Asthma

EAACI 2022 | How Can Biologics Reduce the Use of OCS?
Pulmonology
expert video

EAACI 2022 | How Can Biologics Reduce the Use of OCS?

EAACI 2022 | Long-term Lung Function Improvement Can Be Achieved Through Biologic Use
Pulmonology
expert video

EAACI 2022 | Long-term Lung Function Improvement Can Be Achieved Through Biologic Use

EAACI 2022 | What Is the Potential for Biologics to Help Patients Achieve Remission?
Pulmonology
expert video

EAACI 2022 | What Is the Potential for Biologics to Help Patients Achieve Remission?

Patient Case Discussion
Pulmonology
expert video

Patient Case Discussion

EAACI 2022 | Expanding the Breadth of Type 2 Inflammation in Pediatric Severe Asthma
Pulmonology
expert video

EAACI 2022 | Expanding the Breadth of Type 2 Inflammation in Pediatric Severe Asthma

EAACI 2022 | The Role of Biomarkers in Pediatric Severe Asthma
Pulmonology
expert video

EAACI 2022 | The Role of Biomarkers in Pediatric Severe Asthma

EAACI 2022 | Taking a Breath: A Fresh Perspective on Lung Function and Exacerbations in Pediatric Severe Asthma
Pulmonology
expert video

EAACI 2022 | Taking a Breath: A Fresh Perspective on Lung Function and Exacerbations in Pediatric Severe Asthma

EAACI 2022 | Recognizing Eosinophilic Esophagitis in the Allergy Clinic
Gastroenterology
expert video

EAACI 2022 | Recognizing Eosinophilic Esophagitis in the Allergy Clinic

EAACI 2022 | Evaluating Current Standard of Care and Emerging Biologics for Maintenance Therapy in Patients With EoE
Gastroenterology
expert video

EAACI 2022 | Evaluating Current Standard of Care and Emerging Biologics for Maintenance Therapy in Patients With EoE

EAACI 2022 | A Common Thread: Type 2 Inflammation Across Diseases
Type 2 Inflammation
expert video

EAACI 2022 | A Common Thread: Type 2 Inflammation Across Diseases

Type 2 Inflammation in CRSwNP: Interactive Patient Case
Rhinology
interactivity

Type 2 Inflammation in CRSwNP: Interactive Patient Case

Loss of Smell Is a Key Symptom in CRSwNP
Rhinology
interactivity

Loss of Smell Is a Key Symptom in CRSwNP

EAACI 2022 | The Role of Type 2 Inflammation in Loss of Smell in CRSwNP
Rhinology
expert video

EAACI 2022 | The Role of Type 2 Inflammation in Loss of Smell in CRSwNP

Partnering With Patients: Scores That Matter in CRSwNP
Rhinology
interactivity

Partnering With Patients: Scores That Matter in CRSwNP

Seeing the Big Picture: Type 2 Inflammation Shared Across Different Diseases
Type 2 Inflammation
expert video

Seeing the Big Picture: Type 2 Inflammation Shared Across Different Diseases

At the Front Line: Barrier Dysfunction in the Skin, Airways, and Esophagus
Type 2 Inflammation
expert video

At the Front Line: Barrier Dysfunction in the Skin, Airways, and Esophagus

Hitting a Nerve: Systemic Effects of Type 2 Inflammation on Neuroimmune Function
Type 2 Inflammation
expert video

Hitting a Nerve: Systemic Effects of Type 2 Inflammation on Neuroimmune Function

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

EAACI 2022 | Can We Break the Cycle of Lung Function Decline and Asthma Exacerbations Driven by Type 2 Inflammation in Asthma?
Pulmonology
expert video

EAACI 2022 | Can We Break the Cycle of Lung Function Decline and Asthma Exacerbations Driven by Type 2 Inflammation in Asthma?

Pediatric Asthma Patient Case Tool: Ash
Pulmonology
interactivity

Pediatric Asthma Patient Case Tool: Ash

Adult Asthma Interactive Patient Cases
Pulmonology
interactivity

Adult Asthma Interactive Patient Cases

EAACI 2022 | Redefining Pediatric Severe Asthma and the Future of Clinical Management
Pulmonology
expert video

EAACI 2022 | Redefining Pediatric Severe Asthma and the Future of Clinical Management

Type 2 Inflammation Digital Assessment Tool
Pulmonology
interactivity

Type 2 Inflammation Digital Assessment Tool

The Pathophysiology of Type 2 Inflammation in CRSwNP
Rhinology
interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

The EPI-CARE and PEDISTAD Studies Provide Real-World Assessment of Atopic Dermatitis Prevalence and Burden in Pediatric Patients
Dermatology
expert video

The EPI-CARE and PEDISTAD Studies Provide Real-World Assessment of Atopic Dermatitis Prevalence and Burden in Pediatric Patients

The Burden of Atopic Dermatitis in Children and Their Caregivers – Amerio
Dermatology
expert video

The Burden of Atopic Dermatitis in Children and Their Caregivers – Amerio

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ChinaChange country/region